Podcasts about Bayer

Sermon delivered on the Sixteenth Sunday After Pentecost, 2026, at Queen of All Saints Mission in Hammond, Louisiana, by Rev. Tobias Bayer. Epistle: Eph. 3, 13-21 | Gospel: Luke 14, 1-11   

It was a bonus season for works' teams as Philips and Bayer both got to revel in the reflected glory of PSV and Leverkusen in European competition. There was also the fairytale in Mechelen, some ridiculous comebacks in the UEFA Cup and Graeme Souness up to his old tricks. Martyn and 80s&90sFootball's Michael Hamlen run us through perhaps the last of this collection of chaotic seasons in European competition before Serie A restore some order soon. If you want weekly exclusive bonus shows, join our Nessun Dorma community chat, want your episodes without ads and a couple of days earlier or just want to support the podcast, then head over to ⁠⁠⁠patreon.com/NessunDormaPodcast⁠⁠⁠ where you can subscribe for less than £5 a month. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show

This episode covers:  The role of AI in heart failure and prevention AI advances in interventional cardiology Training cardiologists of the future Host: Fielder Camm Guests: Benjamin Meder, Pim van der Harst, Jozine ter Maaten and Mark Westwood Want to watch that episode? Go to: https://esc365.escardio.org/event/2554 Disclaimer: ESC TV Today is supported by Novartis and Novo Nordisk through independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Dan Atar, Yasmina Bououdina, Fielder Camm, Nicolle Kraenkel, Jozine Ter Maaten, Pim Van der Harst and Mark Westwood have declared to have no potential conflicts of interest to report. Carlos Aguiar has adeclared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Benjamin Meder has declared to have potential conflicts of interest to report: Alexion, Alynlam, Amgen, Apple Inc., AstraZeneca, Bayer AG, BNK, Biontech, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Daiichi Sankyo, Deutsche Gesellschaft für Kardiologie, German Center for Cardiovascular Research, German Research Foundation, Hummingbird Diagnostics, Intellia, Johnson&Johnson, Klaus-Tschira Foundation, Informatics for Life, Leducq Foundation (CASTT), Novartis, Novo Nordisk, Pfizer, SA, Sixt, SMT, Space X, Zoll. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Der DAX legt nach der Zinserhöhung der US-Notenbank 0,7 % auf 25.717 Punkte zu, der EuroStoxx50 gewinnt 1,0 % auf 6.326 Zähler. Rückenwind kommt von der klareren Fed-Linie im Kampf gegen die Inflation und vom nachgebenden Ölpreis. Bilfinger bricht nach einer Prognosesenkung zeitweise um mehr als 26 % ein. Der Konzern senkt Umsatz- und Margenziele und will im Rahmen des Programms "Agile" weltweit bis zu 1.500 Stellen abbauen. Berentzen springt nach bestätigten Übernahmegesprächen mit dem US-Konzern Sazerac kräftig nach oben. RTL Deutschland und Sky wollen bis Ende 2027 rund 500 Stellen streichen. Bayer erhält in den USA eine erweiterte Zulassung für Kerendia. Volvo Cars plant bis 2030 insgesamt 13 neue Modelle. Bei Qiagen sorgen neue Übernahmespekulationen für Kursgewinne. Börsenweisheit von Benjamin Graham: "Das Hauptproblem des Anlegers, vielleicht sogar sein schlimmster Feind, ist wahrscheinlich er selbst."

Rodica Busui, MD, PhD, Jordan Schnitzer Chair in Diabetes; Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition; Director, Harold Schnitzer Diabetes Center, OHSU, School of MedicineCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link:⁠ ⁠ https://forms.cloud.microsoft/r/QfT0PXySCt⁠ or copy & paste into your browser).Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee Disclosure -The planning committee have no relevant financial relationships with ineligible companies. Speaker Disclosure - Rodica Busui, MD, PhD, has disclosed financial relationships with Bayer, Novo Nordisk, Roche, Lexicon Pharma, and Vertex. All relevant financial relationships have been reviewed and mitigated in accordance with ACCME Standards. Dr. Busui does not plan to discuss unlabeled or unapproved uses of pharmaceuticals or medical products.Original Date: September 15, 2026End Date: September 15, 2027

Rodica Busui, MD, PhD, Jordan Schnitzer Chair in Diabetes; Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition; Director, Harold Schnitzer Diabetes Center, OHSU, School of MedicineCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link:⁠ ⁠ https://forms.cloud.microsoft/r/QfT0PXySCt⁠ or copy & paste into your browser).Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee Disclosure -The planning committee have no relevant financial relationships with ineligible companies. Speaker Disclosure - Rodica Busui, MD, PhD, has disclosed financial relationships with Bayer, Novo Nordisk, Roche, Lexicon Pharma, and Vertex. All relevant financial relationships have been reviewed and mitigated in accordance with ACCME Standards. Dr. Busui does not plan to discuss unlabeled or unapproved uses of pharmaceuticals or medical products.Original Date: September 15, 2026End Date: September 15, 2027

Rosyjski atak dosięgnął rejonu zaledwie 800 metrów od polskiej granicy, a Donald Tusk ostrzega przed miesiącami bardzo intensywnych działań Rosji. Tymczasem ropa kosztuje ponad 100 dolarów za baryłkę, strategiczny saudyjski rurociąg East–West pozostaje problemem dla rynku, a ministrowie energii G20 spotykają się w Houston.W PB Brief także: USA mają objąć sankcjami duży bank za związki z Iranem, rusza największe IPO w historii Afryki, Bayer walczy o ugodę wartą 7,25 mld USD, Polska dyskutuje o ponad 180 mld zł z programu SAFE, Apple wypuszcza iOS 27, a były badacz OpenAI i Anthropic ostrzega przed kolejnym etapem rozwoju AI.Do tego najnowszy obraz rynków, dane BIS o globalnym zadłużeniu, przegląd Pulsu Biznesu i ⁠rozmowa z Łukaszem Koryckim o MSPO i wejściu firm cywilnych do sektora obronnego.⁠

Der Wochenstart bleibt schwierig: Der DAX verliert 0,5 % auf 25.441 Punkte, der EuroStoxx50 1,1 % auf 6.254 Punkte. Brent steigt zeitweise auf rund 109 USD, europäisches Erdgas bis auf 84,20 Euro je Megawattstunde. Neue Angriffe auf Saudi-Arabien und Schiffe im Golf verschärfen die Sorgen um die Energieversorgung. Gleichzeitig erreicht die Rendite zehnjähriger US-Staatsanleihen die Marke von 5 %. Vor der Fed-Sitzung steigt damit der Zinsdruck. Zusätzlich geraten KI-Aktien weltweit unter Druck. Hochtief fällt 9,8 %, Infineon 7,7 %, Aixtron 11,2 %. Deutsche Börse gewinnt 2,1 % wegen Spekulationen über Euronext. Novo Nordisk tritt künftig als Novo auf, Sanofi beteiligt sich mit 26,4 % an Cheplapharm. Bayer wartet nach der Roundup-Anhörung weiter auf die Entscheidung. Börsenweisheit von Gerald Loeb: "Der wichtigste einzelne Faktor für die Börse ist die Psychologie der Anleger."

Bret Weinstein speaks with Joel Salatin, whom he calls “one of the wisest people” he's ever met, on the subject of soil, stewardship, and the kind of knowledge you can only get by doing.Find Joel Salatin, owner of Polyface Farm on X at https://x.com/JoelSalatin and https://www.thelunaticfarmer.com*****Sponsors:Sundays For Dogs: Dog food so tasty and healthy, even husbands swear by it. Go to http://www.sundaysfordogs.com/DARKHORSE to receive 50% off your first order.Vanman: Go to https://vanman.shop/darkhorse26 and use code DARKHORSE26 for 15%  off your first order.Redmond Salt: Jurassic-era salt from Utah, and amazing electrolytes (Re-Lyte) from the same sea bed. Go to http://redmond.life/darkhorse and use code DARKHORSE to get 15% off your first order.*****Join DarkHorse on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comCheck out the DHP store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://www.darkhorsestore.orgMusic: "Marble Machine" by WintergatanThis track can be downloaded for free at www.wintergatan.netFree License to use this track in your video can be downloaded at www.wintergatan.net*****Mentioned in this episode:Polyface Farm https://polyfacefarm.comEverything I Want to Do Is Illegal: War Stories from the Local Food Front https://amzn.to/4gS6rD7  (commission earned)Beavers? Bret Weinstein Speaks with Jakob Shockey https://www.youtube.com/watch?v=YBmKwQ9SPt0Brownstone Institute https://brownstone.org The Omnivore's Dilemma by Michael Pollan https://amzn.to/46oGfd5 (commission earned)Greening the Desert Project (Geoff Lawton) https://www.greeningthedesertproject.org*****Timestamps:00:00:00 One of the Wisest People 00:01:15 Trump Spent His Political Equity00:03:37 Sponsor: Sundays for Dogs00:05:26 Sponsor: VanMan00:07:19 Who Benefits? Bayer, JBS, & Trump00:11:37 There Are No Global Problems00:15:24 The Farm You Can Feel00:19:30 Sponsor: Redmond Relyte00:24:03 Biological or Mechanical?00:28:13 Where Hubris Should Be Humility00:31:32 Dominion Is a Destructive Idea00:37:55 Petroleum Was Our Chance to Repair00:39:35 North America Grew More Food in 150000:43:35 All True Stories Must Reconcile00:48:35 Ice Age or Crispy Critters?00:55:08 Bret's Stadium of What He's Burned00:57:31 Learn a Skill01:01:54 Not Wrong to Feel Betrayed01:03:46 Everything I Want to Do Is Illegal01:10:23 Who Should Inspect Your Carrot?01:18:28 All Regulations Are Scale Prejudicial01:21:04 Food EmancipationSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small cell lung cancer (NSCLC). This approval is based on promising Phase 1/2 clinical data, highlighting zipalertinib's role as a tyrosine kinase inhibitor targeting specific genetic mutations. This development is part of a broader trend towards precision medicine in oncology, allowing treatments to be specifically tailored to patients' genetic profiles. The potential impact on patient care is substantial, offering more effective treatment options for those with this particular HER2 mutation. In parallel, Johnson & Johnson's Imbruvica (ibrutinib) regimen has been endorsed by NICE for mantle cell lymphoma. These advancements represent a significant shift towards integrating precision medicine into oncology, aiming to improve outcomes by focusing on individual patient needs. On the business front, Samsung Biologics has secured a $262 million manufacturing deal with an unnamed European pharmaceutical company. This highlights an increasing demand for biologics manufacturing capabilities and reflects a growing reliance on contract development and manufacturing organizations (CDMOs) to meet complex therapeutic needs. Meanwhile, EMD Serono's acquisition of PostEra's AI-discovered fertility programs marks a pivotal move towards incorporating artificial intelligence in drug discovery, potentially revolutionizing women's health and fertility treatments. Clinical trial successes continue to drive momentum in the sector. AbbVie's Qulipta (atogepant) achieved its primary endpoint in a Phase 3 trial focused on menstrual migraines through CGRP receptor antagonism. This positions Qulipta as a promising new therapy within neurological disorders. Similarly, Rezera's Ruvonoflast met its primary endpoint in treating peripheral artery disease via NLRP3 inhibition, showcasing innovative anti-inflammatory approaches within cardiovascular medicine. Investment remains robust across the industry landscape. Frazier Life Sciences has successfully raised $1.1 billion to support small to mid-cap biotech companies, aiming to foster innovation and support emerging firms through critical phases of drug development. Additionally, CordenPharma's €80 million investment in enhancing aseptic fill-finish capacity illustrates strategic expansions within pharmaceutical manufacturing infrastructure. However, regulatory challenges persist. NICE's rejection of Gilead Sciences' lenacapavir due to cost concerns underscores ongoing debates around drug pricing and accessibility within healthcare systems. Furthermore, Biohaven Pharmaceuticals faces a partial clinical hold by the FDA on its epilepsy drug trial due to safety concerns. These instances highlight the rigorous scrutiny required throughout drug development processes. In response to these challenges, companies are increasingly adopting sophisticated strategies to navigate the evolving regulatory landscape. The "most favored nation" pricing policy in the U.S., designed to align domestic drug prices with those abroad, is prompting pharmaceutical firms to reassess their market strategies amid shifting economic conditions. On an optimistic note, Encoded Therapeutics has raised $275 million in Series F financing aimed at advancing gene therapies for conditions like Dravet syndrome. This substantial investment underscores confidence in gene therapy as a transformative approach for treating complex neurological and rare diseases. Finally, Ionis Pharmaceuticals achieved a breakthrough with its therapy approval for Alexander disease, illustrating the growing emphasis on targeting genetic disorders through precision medicine approaches. Such developments reflect both the dynamic nature of scientific innovation and the inherent challenges that accompany it. As these advancements unfold across various therapeutic areas and technological innovations continue to transform industry practices, it becomes increasingly clear that strategic planning and investment in research are crucial for translating scientific breakthroughs into tangible patient benefits. The ability of companies to innovate while ensuring compliance and economic viability will be pivotal as they strive to redefine treatment paradigms within this highly competitive sector. Thank you for joining us today on Pharma Daily. Stay tuned for more updates as we continue to bring you the latest insights from the ever-evolving pharmaceutical and biotech industries.Support the show

Send us Fan MailFor decades, antiplatelet therapy has been central to secondary prevention following noncardioembolic ischemic stroke. Could factor XIa inhibition offer another approach?Dr. Mike Sharma, principal investigator and first author of OCEANIC-STROKE, joins Dr. Maha Othman and Dr. Jameel Abdulrehman to discuss the phase 3 trial of asundexian for secondary stroke prevention.OCEANIC-STROKE randomized 12,327 patients with noncardioembolic ischemic stroke or high-risk TIA to asundexian or placebo in addition to antiplatelet therapy. Ischemic stroke occurred in 6.2% of patients receiving asundexian versus 8.4% receiving placebo, while rates of ISTH major bleeding were similar.The discussion explores why factor XIa is an attractive therapeutic target, the clinical implications and limitations of the results, patient selection, and why factor XIa inhibition may challenge conventional thinking about antithrombotic therapy.This episode was made possible through financial support from Bayer Inc. Thrombosis Canada maintained full editorial independence, and Bayer had no involvement in the selection of the guest, development of the questions, conduct of the interview, or review or approval of the final content.Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R. Asundexian for secondary stroke prevention. New England Journal of Medicine. 2026 Apr 16;394(15):1467-79.Support the showhttps://thrombosiscanada.caRegister today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026ConferenceTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Heavy menstrual bleeding affects approximately one in four women of reproductive age, yet many patients remain undiagnosed, undertreated, or unaware that effective treatment options exist. In this free webinar, Dr Simone Gonzo explores the assessment and management of heavy menstrual bleeding in general practice. What you will learn Drawing on the Australian Heavy Menstrual Bleeding Clinical Care Standard, this session provides a structured approach to history-taking, investigation, medical management, and shared decision-making, including when to consider referral for intrauterine system insertion. Designed for busy GPs, the webinar provides practical strategies you can apply immediately in the consultation room to support women experiencing heavy menstrual bleeding. Delivered in collaboration with Bayer Australia^, this session will teach you how to: Evaluate treatment options for heavy menstrual bleeding from adolescence to menopause, including hormonal and non-hormonal treatments, procedural interventions, intrauterine systems and hysterectomy. Plan a counselling approach that supports shared decision-making between doctor and patient considering all treatment options for heavy menstrual bleeding. The webinar includes Q&A and case discussions. ^ This activity has been developed independently by HealthCert Education with the support of an unconditional educational grant from Bayer Australia. Bayer has had no editorial input into the content. Watch the webinar here.    Access a free women's health course As an RACGP/ACRRM-accredited education provider, we're required to evaluate our accredited activities, and we would really appreciate your feedback on this webinar.  The evaluation takes just a few minutes and helps us understand what you took away from the session and how we can continue improving our education. As a thank-you for completing the evaluation, you'll receive complimentary enrolment in a women's health short course of your choice, valued up to $295.

Have you been told your whole life to eat more fiber and drink more water - and you've been doing exactly that for years, and you still are constipated?Do you have a whole cabinet of magnesium — citrate, oxide, the powder everyone on Instagram swears by — and none of it works?Have you been on MiraLAX so long you can't remember the last time your body did this on its own?Or - have laxatives and enemas failed working for you completely to get constipation relief?If you said yes to ANY of those questions, then this episode is for you.In today's episode, I'm walking you through what the constipation research actually says about how often these things work (the real success rates!) and set you free from thinking you just need to up your dose or try another different brand. Today I'll be breaking down:Does fiber actually work for constipation - the real effectiveness number across sixteen randomized trialsDoes magnesium work for constipation - it was WAY less effective than I guessed it'd beDoes drinking more water help constipation - what one meta-analysis revealed in a 141 person studyHow well MiraLAX holds up to research — including the number from Bayer's own funded research If you are tired of being handed the same four pieces of advice and you do not want to spend one more year trying the same things over and over again that aren't changing anything — then this episode is for you. TIMESTAMPS:00:00 - Why Nothing Works 02:00 - Podcast Welcome 03:08 - New Constipation Series 04:54 - Why Research Matters 07:53 - Fiber Success Rates 12:18 - Magnesium Reality Check 13:45 - Does Water Help 18:47 - MiraLAX Effectiveness 19:53 - You Didn't Fail 20:53 - Clear Challenge Invite 24:03 - Next Week Root Causes 25:22 - Final Wrap Up EPISODES MENTIONED:178// Why Constipation Medicine Isn't Helping You + What to Do When Laxatives, Probiotics, Water, and Fiber Aren't Healing Your Constipation313// Magnesium Citrate for Constipation Relief: Why It Fails + What to Do Instead165// The Constipation Magnesium Myth WORK WITH US:Option #1)

Vom Bayer-Standort im Wedding aus wird die globale Versorgung mit verschreibungspflichtigen Arzneimitteln gesteuert; es wird produziert und geforscht. Bettina von Streit leitet den Standort seit rund zwei Jahren, und hat etwas zu sagen. Von Jan Pallokat

The following article of the Agribusiness & Food industry is: “Closing the Gender Gap in Science and Technology” by Laura Tamayo, Director of Public Affairs, Communication and Sustainability, Bayer. (AA2587)

Sermon delivered on the Fifteenth Sunday After Pentecost, 2026, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer Epistle: Gal. 5, 25, 26; 6, 1-10 | Gospel: Luke 7, 11-16

In this episode, we examine new farm-level evidence suggesting phosphorus is coming into balance on farms in the River Wye catchment – and ask what it means for water pollution. We visit a field trial where precision breeding could make UK-grown soya commercially possible. We examine the continuing decline in cattle and sheep numbers, and run the rule over the latest livestock and arable markets. And we discover why some of Britain’s biggest music names are heading to Suffolk for a harvest festival with a difference. This episode is brought to you by Bayer Crop Science – weeding out uncertainty. Chapters 00:00 – Introduction00:51 – River Wye: are farmers turning the tide on pollution?10:18 – Bayer autumn drilling update: tackling weeds field by field12:20 – Could gene-edited soya become a UK break crop?21:51 – Farming news: El Niño, Asian hornets and SFI2626:07 – Why are Britain’s beef and sheep herds shrinking?32:21 – Markets: beef firms as grain prices rise34:59 – A Great British Harvest Festival with a difference42:13 – That’s all for this week Guests Dan Smith – farm facilitator, Herefordshire Rural Hub Rachel Banks – technical manager, Bayer Crop Science Dr Frank Röber – Europe Breeding Alliances lead, Corteva Agriscience Philip Case – Farmers Weekly Prys Morgan – beef and lamb sector director, AHDB Andrew Sunnucks – farmer and music producer Useful links River Wye nutrient balance projectRiver Wye water quality – Environment AgencySFI26 Window 2AHDB Beef & LambBayer Crop ScienceGreat British Harvest Festival This episode of the Farmers Weekly Podcast is co-hosted by Johann Tasker, Louise Impey and Hugh Broom. Edited and produced by Johann Tasker. To get in touch with the Farmers Weekly Podcast: - Contact or follow Johann: linkedin.com/in/johanntasker/ Contact or follow Louise: linkedin.com/in/louise-impey-95470b20b/ Contact or follow Hugh: linkedin.com/in/hugh-broom-9b11906a/ For Farmers Weekly, visit fwi.co.uk or follow linkedin.com/company/farmers-weekly To contact, sponsor or advertise on the Farmers Weekly Podcast, email podcast@fwi.co.uk. In the UK, you can also text the word FARM followed by your message to 88 44 0. See omnystudio.com/listener for privacy information.

Your clothes, your mattress, your cleaning products — they're all off-gassing chemicals into your body 24 hours a day, and most people have no idea. Alex Clark has spent the last year on the front lines of the MAHA movement, testifying at the White House on glyphosate, exposing what's hiding in cotton tampons, and building one of the most-followed health podcasts in the country — and today she's bringing all of it to this show. **In this episode:** - Alex's viral $60 morning smoothie — every ingredient, the science behind each one, and whether it's actually setting her up for a blood sugar crash - Why glyphosate is lurking in places most people never consider: tampons, clothing, and baby products — and what $16 billion in Bayer settlements tell you about the "safe" science - The problem with polyester blankets, synthetic socks, and fast-fashion baby clothes — and why your skin absorbs what sits on it the same way your gut does - What really happened when Alex and her coalition were invited to a White House roundtable to confront the current administration's handling of glyphosate policy - The truth about freshly milled flour, sourdough, and why the last two weeks of ripening are when most of a food's nutrition actually develops - How to clean your air, replace your bedding, and swap your cleaning products — practical first steps that cost less than you think Uncover what's really going on in your body with advanced biomarker testing for hormones, thyroid, and metabolism— plus a 1-hour consultation with a Senior Health Advisor! →  http://mybloodwork.com *Disclaimer: The bloodwork our team runs at mybloodwork.com covers a handful of the biomarkers listed in the guide above — including critical thyroid and metabolic markers — plus a 1-hour consultation with a Senior Health Advisor, but does NOT cover all 25. You will want to consult your primary or functional doctor for the entire list. Thank you to our sponsors! Sunlighten Sauna: https://get.sunlighten.com/axepodcast Manukora Manuka Honey: https://manukora.com/axe Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: https://www.youtube.com/@drjoshaxe?sub_confirmation=1

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

GET CHLORINE DIOXIDE SOLUTIONS HERE: https://frontierpharm.com?sca_ref=11953077.06TP4RWJ73 Use code WAM to save on your order! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/wam USE Code WAM to save 25% plus free shipping! USE Code WAM50 for 50% off on select items like the #10 cans & MRE packs! Pledge here! Just a dollar a month can help keep us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 EXCLUSIVE replays of hour plus long live shows are available here at $5 a month or more! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! DONATE HERE: https://gogetfunding.com/help-keep-wam-alive/# Help save WAM! Josh Sigurdson reports on the crazy failure of the so-called "MAHA" movement by President Trump not only endorsing glyphosate and pushing for increased production of the chemical compound in Roundup but ALSO, shielding them from legal liability. President Trump ran on a platform promising to stop processed foods being pushed on children as well as cracking down on things like Bayer/Monsanto's "glyphosate." Instead, he has written an order to increase production of the chemical, a complete 180. Why are these companies shielded from legal liability? Countless lawsuits were being paid out due to cancer risks from glyphosate. We also see massive increases in Parkinson's Disease among people who live near golf courses who spray the courses down with glyphosate. We are talking about a 126% increase. This also includes Diquat which is what Bayer uses in their "glyphosate free" RoundUp which according to studies is 200X more toxic. There are currently 60,000 ongoing lawsuits against Bayer/Monsanto and still, President Trump gives Bayer immunity. RFK Jr. recently said on Joe Rogan that he was disappointed in this decision, but he still signed the paper. We delve into this issue as well as the Tennessee teen Arden Allison who fought a giant tumor for 7 years following accidentally dousing himself in glyphosate. This report is from our live Sunday show which you can find the complete episode of on Patreon. Stay tuned for more from WAM! GET 10% OFF ON SHILAJIT FROM DR. KAUFMAN WHEN YOU USE CODE WAM10 HERE: https://medauthentica.com/discount/WAM10?redirect=/products/authentica-shilajit%3Fsca_ref=10867124.wrNV3jkYSaMg9 GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2026

Neoborn Caveman is back with the untamed, unedited live radio show — marble-mouthed, vivid, nothing planned. He starts on America founded as a republic by the people for the people, and on how little of the official story still stands. From there NC looks at a UK car park where cash is banned, only the app still counts, and the fine is what you get for showing up with money and a working phone — sovereignty taken one payment at a time. After that Neoborn turns to Chinese cabbage dipped in formaldehyde and sold in Australia, but fear not, he offers a solution anyone can do to stay healthier. Later he takes the Havasupai trail in Arizona, a mother slashed after asking for directions. NC then investigates Network for Hope in Kentucky, the organ outfit HHS began decertifying under RFK Jr. after procurement started while patients still showed signs of life. He closes on the 1980s Pizza Hut revival and the real reasons people are driving back to those rooms, and finally on schools that spent three trillion and left three in ten proficient, and on heaven starting from within.Music guests: Big Sexy, Carlyle, Inoxidables, Van Hechter 00:00:00 On This Day Today - (no freedom yet)00:06:06 Big Sexy: Hiding in Romeo00:09:46 Fined for Not Having the App00:18:28 Carlyle: Without the Weed00:21:51 Formaldehyde Cabbage and Eating Where You Live00:30:14 Inoxidables: Sirena00:33:59 Wash Your Fruit and Veggies: Pesticides, Glyphosate, and Bayer00:44:00 Neoborn Caveman: Counterfeit Love00:46:28 A Hike, a Knife, Tolerating Crime00:56:08 Van Hechter: Boy Problems01:00:20 Organ Harvesting Comes Home: Network for Hope01:06:57 Big Sexy: This City Knows My Name01:10:17 Retro Pizza Hut, Hollowed-Out Schools, and Heaven Within01:23:05 Neoborn Caveman: Final ShowKey TakeawaysAmerica was founded as a republic by the people for the people. The rest of that sentence is the part he tells you to add yourself.Cash banned at the gate is not a parking story. It is sovereignty taken one payment at a time.Wash produce. Tap water takes some of the spray off. Baking soda or vinegar takes more. Do not soak strawberries.Glyphosate showed up in most of the urine samples he cited. IARC called it carcinogenic. Bayer, which once sold heroin as cough syrup, still defends the spray.A mother was slashed in the neck on the Havasupai trail after asking a stranger for directions. Tolerating that is accepting the next one.Network for Hope began procurement while patients still showed signs of life. HHS started decertification under RFK Jr.Retro Pizza Hut rooms are filling again.Sound Bites“Shouldn't we have, I don't know, an American Republic instead of the American Empire?”“We absolutely know nothing about anything. Or we know nothing about everything. Or we know everything about nothing.”“How can we be satirical when we live already in hell?”“Smartphones are tracking devices, so only dumb people use smartphones.” “Hey, I am dumb, are you?”“For a glass of water you have to have an app. To wipe your buttocks you have to have an app.”“So kids, what a book is? It's a phone you could open, okay?”“We should have a constitutional right for cash.”“You won't live longer if you embalm your body from within.”“The same company that invented the synthetic cocaine called, ready, steady go, heroin.”“Tolerating crime is idiocy.”“Not overrun by… we can't say this in the show.”“GET THE FORK OUT OF OUR LIVES!”“Sex is better if you do at home, not at Pizza Hut.”“We are humans for heaven's sake. Not for hell, but heaven.”“Heaven starts from within.”“The new old world order can't take away unless you give it up, voluntarily.”Join the tea house at patreon.com/theneoborncavemanshow. Support the show. Be real.Remember: you are worthy, you are amazing, you are one of a kind!Keywords: Overrun by Life, republic, cash, parking app, digital control grid, formaldehyde cabbage, wash produce, glyphosate, Bayer, Havasupai, Network for Hope, organ harvesting, RFK Jr., Pizza Hut, Rockefeller education, heaven starts from withinHumanity centered satirical takes on the world & news + music - with a marble mouthed host.Free speech marinated in comedy.Supporting Purple Rabbits.Viva los Conejos Morados. Hosted on Acast. See acast.com/privacy for more information.

...sagt zumindest das Elversberg-Orakel Mike Kleiß. Ihr erstes Spiel in der Bundesliga hat die ELV gegen die Millionentruppe von Bayer 04 Leverkusen sehr stark gewonnen. Thomas Wagner bleibt bei seiner Analyse deutlich mehr auf dem Boden. Wagner und Kleiß eint jedoch die Sorge um Werder Bremen. Was ist da los hinter den Kulissen? Und beide gratulieren dem FC Bayern München schon am ersten Tag zur Meisterschaft

Podcast: ICS Cyber Talks PodcastEpisode: Ophir Oren, Head of Cyber & AI Sec Innovation @Bayer on protecting against a Future only a step awayPub date: 2026-08-26Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationהמשמעות של חדשנות בעידן החדש היא פחות או יותר "מחר", היכולת שלנו כאנשי סייבר להסתמך על כלי הגנה קיימים הולכת ומצטמצמת ודורשת להערך מחדש במשך שנים אני טוען שסייבר זו לא טכנולוגיה אלא מכלול תבונות שהטכנולוגיה בקצה נועדה לשרת אותן, כיום בעידן האינטלגנציה המלאכותית והיכולות המשתנות חדשות לבקרים, ברור שאין יותר מקום להסתמך רק על טכנולוגיות הגנה היות והן משתרכות מאחור בלשון המעטה ןמעבר להגנה לפי קונטקסט. נחשון פינקו מארח את אופיר אורן ראש צוות חדשנות בסייבר ואינטליגנציה מלאכותית בחברת באייר בשיחה על תפיסת החדשנות והגורם האנושי מול התפתחויות טכנולוגיות על סטרואידים. בין שאר הנושא: סוכני אינטליגנציה מלאכותית ה"אשליות" של האינטליגנציה מלאכותית זהויות לא אנושיות   קונטום והעידן הפוסט קוונטי מעבר מערכות תפעוליות לענן ועוד   The Meaning of Innovation in the New Era Is, More or Less, “Tomorrow.” As cybersecurity professionals, our ability to rely on existing security tools is steadily diminishing, requiring us to fundamentally rethink our approach. For years, I have argued that cybersecurity is not a technology problem. It is a collection of human insights, intelligence, and ways of thinking, with technology merely serving those capabilities at the edge. Today, in the age of artificial intelligence and rapidly evolving capabilities that change almost daily, it's clear there is no longer room to rely solely on defensive technologies. To put it mildly, they are falling behind, even when moving beyond traditional context-based protection. Nachshon Pincu hosts Ophir Oren, Head of Cybersecurity Innovation and AI at Bayer, for a conversation about innovation, the human factor, and technological developments on steroids. Among the topics we discussed: AI Agents The “hallucinations” of artificial intelligence Non-human identities Quantum computing and the post-quantum era The migration of operational technology (OT) systems to the cloud And much more   Cybersecurity is no longer about keeping pace with technology. It is about anticipating what comes next.The podcast and artwork embedded on this page are from Nachshon Pincu, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

This Day in Legal History: The Murder of Emmett TillOn August 28, 1955, fourteen-year-old Emmett Till was abducted, tortured, and murdered in the Mississippi Delta by two white men, Roy Bryant and J.W. Milam, after Till—a Black teenager visiting from Chicago—was accused of offending a white woman in a grocery store. His killers beat him, shot him, weighted his body, and threw it in the Tallahatchie River. He was a child, and his murder, and what came after, helped ignite the modern civil rights movement.The legal story is one of justice utterly failing, and then, slowly, refusing to disappear. Bryant and Milam were tried the next month in a segregated Mississippi courtroom. The trial lasted five days; the all-white, all-male jury deliberated for barely an hour before acquitting both men, with one juror later saying it wouldn't have taken that long if they hadn't stopped for a soda. Protected by double jeopardy, the two men then sold their confession to a magazine for a few thousand dollars, describing in detail how they'd killed the boy they had just been acquitted of murdering. It was one of the starkest demonstrations imaginable that the machinery of Southern justice was not built to deliver justice to Black victims.The significance of August 28, 1955 reaches across the decades. Emmett's mother, Mamie Till-Mobley, made the searing decision to hold an open-casket funeral and let the world photograph her son. That act of witness galvanized a generation. And there is a haunting piece of calendar symmetry worth honoring: exactly eight years later, on August 28, 1963, Martin Luther King Jr. stood at the Lincoln Memorial and delivered the “I Have a Dream” speech to the March on Washington. The law eventually, partially, caught up—the Civil Rights Act, the Voting Rights Act, and, only in 2022, a federal anti-lynching law that bears Emmett Till's name. It's a reminder that some of the most important developments in American law began not in a courtroom win, but in a courtroom failure so profound that the country could not look away.The brothers Andrew and Tristan Tate were back in a Miami federal courtroom this week, shackled, asking a judge to release them on bond while they fight extradition to the United Kingdom. The two, who have built a massive and controversial online following, have been held in a federal detention center since their July arrest on U.K. rape and sex-trafficking charges. Their lawyers made a pointed argument: if Romania, where the brothers face a separate sex-crimes case, is willing to let them remain free pending those proceedings, then a U.S. court should free them too—especially since, they argue, two of the most recognizable men on the internet can't exactly disappear. Prosecutors pushed back hard, and here the law is decidedly against the Tates. In ordinary criminal cases, release pending trial is the norm. But international extradition is different: there is a strong, long-standing presumption against bail, rooted in the idea that the United States has a treaty obligation to actually produce the person for the requesting country, and that letting an extradition target go free risks a diplomatic and legal failure if they flee. Courts generally require “special circumstances” to grant bail in an extradition case—a demanding standard—and prosecutors noted the brothers have money and have bragged about holding multiple passports. Legal experts quoted in the coverage thought it unlikely they'd win release. The significance is a useful window into a corner of the law most people never see: that fighting extradition is not like fighting ordinary charges, and the presumption of liberty that normally protects defendants is largely flipped when a foreign government is waiting to prosecute.Tate brothers press for release from US jail during extradition fight | ReutersPBS NewsHour · NPRA federal appeals court has cleared a significant hurdle for Bayer's $7.25 billion settlement of tens of thousands of Roundup cancer claims. The Eighth Circuit dismissed a challenge by a group of objecting plaintiffs who were trying to derail the deal—and the fight was about forum, which sounds dry but matters enormously in mass litigation. Bayer structured this as a class-action settlement in Missouri state court, an unusual move: it's using a single state-court proceeding to try to resolve claims nationwide. The objectors argued that a state court has no business fast-tracking a nationwide resolution, and that the whole thing belongs in front of the federal judge already overseeing the consolidated federal Roundup litigation. A federal judge ruled in June that the case could stay in Missouri state court, and now the Eighth Circuit has agreed, dismissing the appeal. Why does the forum matter so much? Because a settlement that binds a nationwide class of people—including people who haven't actively participated—raises real due-process questions about whether a single state court can bind absent claimants across the country, and because plaintiffs and defendants often have strong strategic preferences about which court, and which rules, govern a mega-settlement. This connects to the Bayer story we covered earlier this summer, when the Supreme Court handed the company a big win on failure-to-warn claims; this settlement is the other half of Bayer's campaign to finally contain a decade of Roundup litigation. A hearing to approve the deal is set for September 14, with roughly 65,000 claims hanging in the balance. The significance is that Bayer is close to buying its way out of a liability that has dogged it for years—and the courts just removed one of the last procedural obstacles.US court dismisses appeal over objections to $7.25 billion Roundup deal | ReutersRTÉ · Maryland Daily RecordAnd finally—though this is anything but a footnote—the biggest story of the week, and arguably the summer: Meta has agreed to pay up to $18 billion and fundamentally change how its apps work for teenagers, settling the landmark case accusing it of designing Facebook and Instagram to addict children. This is the resolution of the very trial we watched begin just ten days ago—the 29-state case in Oakland, with the whistleblower testimony from Arturo Bejar. Rather than let it run to a verdict, Meta settled, and the numbers are staggering: more than $17.6 billion to 48 states, D.C., Puerto Rico, and the territories, plus another $459 million to resolve privacy claims tied to the old Cambridge Analytica scandal. But the money may be the less important part. For the next decade, Meta has agreed to concrete design changes: teens will be capped at two hours a day on the apps, and blocked from using them between midnight and 6 a.m. without a parent's consent. And in a clever pressure mechanism, part of the payout is contingent on whether YouTube and TikTok adopt similar protections—effectively using this settlement to try to move the whole industry. Everything we've tracked all summer led here: the New Mexico verdict, the Tennessee trial, the bellwether cases, the Ninth Circuit clearing these suits past Section 230. This is the reckoning arriving. It still needs approval from Judge Yvonne Gonzalez Rogers, who presided over the trial, but if it holds, it's one of the largest consumer-protection settlements in American history—and, more consequentially, the first time a court-supervised deal will reach inside these platforms and re-engineer them for the safety of kids. The era of treating social media's effect on children as an unregulated externality may have just ended, not with a verdict, but with $18 billion and a clock that shuts the app off at midnight.Meta reaches $18 billion of settlements over children's social media addiction | ReutersCNN · Al Jazeera This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Több ezer lakásvásárló, jelentős banki és kötvényes kitettségek, valamint egy meghiúsult százmilliárdos állami ügylet fut össze a Bayer Construct mostani döntésében. A cég bejelentette, csődvédelemmel próbál időt nyerni és megegyezni a hitelezőivel. De mekkora a baj valójában, és mi történhet, ha ez nem sikerül? Erről volt szó Gulyás Veronikával, a Portfolio újságírójával. A műsor második felében körbejártuk, hogy a Tisza egyik fontos nyugdíjígérete döntéssé vált: januártól emelkedik az öregségi nyugdíjminimum. De kik járnak jól ezzel, mennyibe kerülhet, és mennyit old meg mindez a nyugdíjrendszer problémáiból? Farkas András független nyugdíjszakértőt kérdeztük. Főbb részek: Intro − (00:00) Bayer Construct-csőd − (01:42) Nyugdíjemelés − (14:24) Tőkepiaci kitekintő (28:25) Kép forrása: Balaton József via MTISee omnystudio.com/listener for privacy information.

As people take greater ownership of their health, the role of brands is changing.Recorded live at the Havas Café during the Cannes Lions International Festival of Creativity, this conversation explores how marketing can help people live healthier, longer, and more fulfilling lives.Jim is joined by:Yvonne Bryant, Hemoglobinopathies Commercialization Head at Novo Nordisk, whose career has spanned clinical research, drug development, commercialization, and consumer marketing. Today, she leads commercialization efforts for rare blood disorders, helping translate breakthrough scientific innovation into meaningful patient impact.Lauren Gellman, Senior Director and Head of Marketing for Health and Home at Google. Lauren oversees marketing across Google's health ecosystem, including Fitbit, Nest, and Google Health, where she's helping shape the future of AI-powered health experiences and personalized wellness.Samantha Avivi, Global Chief Marketing Officer for Consumer Health at Bayer. A longtime marketing leader whose career includes roles at Procter & Gamble, Kimberly-Clark, Walmart, and more, Samantha now leads global marketing and innovation across Bayer's portfolio of trusted consumer health brands.Drawing on Havas' Science of Desire research, the conversation explores how healthcare marketers are building trust in the age of AI, making complex science more accessible, and helping people navigate an increasingly personalized health journey. Ultimately, it arrives at a simple but powerful idea: the future of healthcare marketing isn't simply about helping people live longer. It's about helping people live better.—This week's episode is brought to you by Havas and Infillion.—Meet The CMO Podcast On the RoadThe CMO Podcast will be on the road throughout Q4 2026, capturing conversations with the leaders shaping the future of marketing, leadership, and business. If you'll be attending one of these events, we'd love to connect. Let us know!Advertising Week New York | October 5–7BLINK Cincinnati | October 8ANA Masters of Marketing | October 19–22—Interested in partnering with The CMO Podcast?!Looking ahead to the rest of 2026 and into 2027, we're partnering with brands to create executive content platforms that extend far beyond a single event. From pop-up podcast studios and live recordings to executive roundtables, keynote conversations, and bespoke thought leadership programs, we work with partners to build meaningful experiences that connect with senior marketing leaders.Whether you'd like to partner with us at one of the industry's biggest marketing events or create a custom experience designed specifically for your brand, we'd love to explore what's possible. Reach out to learn how we can build something together.Email us at podcasts@vyve.co—Produced by vYveThe CMO Podcast is proudly produced by vYve Production, a full-service production and content studio specializing in podcasts, executive storytelling, branded content, and live experiences. vYve is a community of ambitious leaders dedicated to unlocking what's next in business and in life. Through executive coaching, transformative experiences, strategic content, and communities like The CMO Podcast, vYve helps entrepreneurs, corporate leaders, and teams grow their businesses, strengthen their leadership, and build meaningful connections that last.Learn more about vYve and The CMO Podcast community at www.vyve.co.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sermon delivered on the Thirteenth Sunday After Pentecost, 2026, at Queen of All Saints chapel in Pottstown, Pennsylvania, by Rev. Tobias Bayer. Epistle: Gal. 3, 16-22 | Gospel: Luke 17, 11-19

新學期準備好了嗎？

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the rapidly evolving landscape of pharmaceutical and biotechnology sectors, several significant developments have marked recent progress in drug development, clinical trials, regulatory approvals, and industry partnerships. A landmark partnership between Roche and Hanmi Pharm has been established to develop HM17321, a promising weight loss drug. This collaboration involves a substantial $190 million upfront payment and could reach up to $2.3 billion based on milestone achievements. The high stakes underscore the potential value of addressing obesity through innovative pharmacological interventions, highlighting industry focus on metabolic disorders. Roche's recent $2.5 billion agreement with Hanmi Pharmaceutical emphasizes addressing metabolic disorders through less-explored mechanisms, indicating confidence in its potential to target obesity through novel pathways. Further illustrating industry dynamism, Lundbeck has reported impressive financial performance with a 16% sales growth in the first half of 2026. This growth is driven by the success of Vyepti and Rexulti. Vyepti, an antibody-based therapy for migraine prevention, continues to capture market share due to its efficacy and safety profile. Meanwhile, Rexulti extends Lundbeck's influence in treating major depressive disorder and schizophrenia, solidifying its position in neurological therapies. Significant advancements on the regulatory front have been made for drugs targeting rare diseases and neurological disorders. Spruce Biosciences is advancing toward a fourth-quarter FDA filing for its Sanfilippo syndrome drug following successful manufacturing discussions. This enzyme replacement therapy targets an ultra-rare lysosomal storage disorder with profound neurological impacts on affected children—a vital step forward in addressing unmet medical needs in rare diseases. Moreover, multiple drug approvals across various regions underline regulatory successes. The European Commission has approved Acadia Pharmaceuticals' Daybue (trofinetide) for treating neurobehavioral symptoms in Rett syndrome patients. This approval follows successful Phase 3 trial results and marks an important milestone in managing this severe neurodevelopmental disorder. Similarly, Takeda's Orzeyful (oveporexton), a first-in-class orexin receptor agonist for narcolepsy type 1, has been approved in Japan, emphasizing advancements in targeting orexin deficiency—a key driver of narcolepsy. In oncology developments, Bayer's Hyrnuo (sevabertinib) received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for HER2-mutant non-small cell lung cancer based on promising Phase 1/2 data. This tyrosine kinase inhibitor represents a novel approach to targeting genetic mutations within cancer cells. Additionally, GC Biopharma's Hunterase has gained approval in India and Taiwan for treating Hunter syndrome (mucopolysaccharidosis type II), utilizing enzyme replacement therapy to address this lysosomal storage disorder affecting multiple organs including the central nervous system. Notably, this therapy demonstrates an ability to cross the blood-brain barrier—a significant technical achievement enhancing treatment efficacy. The regulatory landscape is also evolving with new guidelines such as the UK's MHRA clarifying pathways for microbiome-based medicinal products. These developments underscore the growing interest in microbiome therapies as promising approaches to treating infectious diseases. Amidst these advancements, challenges persist as seen with Regenxbio facing a 22% share drop following an FDA clinical hold on its Hunter syndrome gene therapy RGX-121 due to spine MRI findings. This situation highlights inherent risks associated with cutting-edge gene therapies despite their groundbreaking potential. Overall, these scientific developments and regulatory updates illustrate a vibrant pharmaceutical and biotech industry focused on innovative treatments addressing complex diseases. This momentum promises enhanced patient care while signifying a robust pipeline of therapeutic options poised to transform disease management paradigms across multiple domains. The industry continues to witness significant scientific advancements and regulatory shifts. GlaxoSmithKline's (GSK) achievement of securing the world's first regulatory approval for a hepatitis B vaccine in Japan underscores GSK's leadership in infectious disease prevention—a critical advancement in global public health efforts. Moreover, collaboration between Roche and Eli Lilly culminated in FDA approval for an innovative Alzheimer's biomarker blood test. This diagnostic tool offers a groundbreaking development in Alzheimer's disease management by providing a less invasive method for early detection and monitoring—crucial for improving patient outcomes and tailoring therapeutic interventions. On strategic corporate fronts, Daiichi Sankyo is enhancing its oncology portfolio by promoting Ken Keller to head a new commercialization unit aimed at becoming a top-five oncology player by 2035. This reflects broader industry trends toward specialized therapies offering substantial clinical benefits. Cell therapy sector dynamics are also evident as Cellares' CEO plans operational resizing after losing a significant manufacturing client—a reflection of broader industry dynamics where scaling innovative therapies like automated cell therapy requires balancing operational capabilities with market demands. Berry Street's merger with Healthify aims to expand AI-driven metabolic care by integrating Healthify's AI technology with Berry Street's clinical network—aligning trends toward personalized medicine and digital health integration. On the regulatory front, Spruce Biosciences progresses towards filing for FDA approval of its ultra-rare disease drug candidate emphasizes commitment to developing treatments despite complex pathways promising significant impact for underserved populations. Lastly, TME Pharma remains optimistic about its brain cancer drug nearing partnership conclusions reflecting confidence despite competitive pressures—highlighting key scientific advancements shaping pharmaceutical landscapes emphasizing innovative therapies' focus on improving patient care outcomes through enhanced diagnostics novel therapeutics comprehensive healthcare solutions. Recent developments highlight significant scientific advancements poised to influence patient care trajectories as Capricor Therapeutics received a three-month extension from FDA reviewing additional data refined indication Duchenne muscular dystrophy therapy candidate deramiocel set November 22 action date underscoring FDA commitment thorough evaluation processes providing potential new treatment option pending approval. In contrast, Regenxbio faces FDA hold RGX-121 gene therapy candidate aimed at Hunter syndrome due to small nodules cystic masses spines patients registrational trial highlighting ongoing challenges gene therapy rigorous safety assessments complexities developing advanced genetic treatments. With Roche entering substantial agreement Hanmi Pharmaceutical access investigational obesity drug HM17321 next-generation asset aims induce weight loss enhance lean mass positioning potentially transformative therapy burgeoning weight management market reflecting growing interest competition obesity treatments strategic focus expanding metabolic disorder portfolio. Regulatory business maneuvers paralleled broader industry trends including shifts manufacturing strategies essential advanced therapies innovative approaches underscored recent discussions vivo delivery systems reshaping viral vector production improving efficiency scalability potentially lowering costs accelerating time-to-market further highlighting rigorous safety standards governing clinical research drug development processes landscape therapeutic development continues evolve companies like Novo Nordisk trialing lower maintenance doses oral Wegovy obesity treatment gained significant market traction initiatives reflect ongoing efforts optimize dosing regimens enhance patient compliance outcomes collectively underscore dynamic period pharmaceutical biotech sectors characterized scientific innovation strategic investments regulatory scrutiny implications profound patient care new therapies promise address unmet medical needs navigating complex environments adapt changes influence future drug development strategies therapeutic landscapes significantly events signal not only challenges opportunities companies strive bring novel treatments market safely effectively ultimately aiming improve patient outcomes various disease areas poised intersection technological innovation oversight driving advancements hold potential enhance care expand possibilities.Support the show

What happens when burnout, a health crisis, and midlife force you to rethink everything?In this episode of Save Our Sisters Unplugged, Norine Fahie sits down with Ingrid Bayer, bestselling author, international speaker, facilitator, and advocate for women navigating change and reinvention.After emergency spinal surgery and the realization that she was completely burned out, Ingrid began a deeply personal journey of healing, rediscovery, and finding her way back to herself. We talk about recognizing burnout, releasing identities that no longer fit, rediscovering your voice, redefining success, and having the courage to begin again.We also discuss Ingrid's book, Not Done Yet: A Journey Back to You, and its powerful reminder that midlife is not the end—it can be the beginning of a more honest, aligned, and fulfilling chapter.If you've ever wondered, “Who am I now?” or felt the pull to reinvent your life, this conversation is for you.Connect with Ingrid Bayer:Website: https://www.ingridbayer.com/Instagram: https://www.instagram.com/not.done.yet.movement/Facebook Community: https://www.facebook.com/groups/notdoneyetmovementLinkedIn: https://www.linkedin.com/in/ingridbayer/Connect with Save Our Sisters Unplugged:Website: https://www.saveoursisters.netLinktree: https://linktr.ee/saveoursisterssosEmail: saveoursisters2020@gmail.comOne woman's story can unlock another woman's prison.#SaveOurSistersUnplugged #IngridBayer #NotDoneYet #MidlifeReinvention #BurnoutRecovery #WomensEmpowerment #HealingJourney #StartingOver #FindingYourself #WomenSupportingWomen

John welcomes bestselling author, Spy magazine co-founder, and Peabody Award-winning radio host Kurt Andersen for the first installment of a two-part episode focused on his extraordinary new novel, “The Breakup.” After laying out the premise of his first work of speculative fiction—in 2045, two Americans edge towards ending their marriage just as their country, in the wake of a second Civil War, prepares to end its own, much longer union—Andersen discusses how such a national divorce could come to pass, what America might look like in its aftermath, and whether that outcome would actually be so terrible, after all.Bayer is empowering American farms with the smart tools and accurate data needed to confidently advance regenerative agriculture, improving soil health for a sustainable future.

Welcome to RealAg Radio with Shaun Haney! Today on the show Haney is joined by Cam Dahl of Manitoba Pork to talk about the benefits and power of CUSMA, Brenna Grant of Canfax on plant closures/the Canadian beef industry, and Tim Darragh of Bayer for a product spotlight! To round out the show, Haney gives... Read More

Welcome to RealAg Radio with Shaun Haney! Today on the show Haney is joined by Cam Dahl of Manitoba Pork to talk about the benefits and power of CUSMA, Brenna Grant of Canfax on plant closures/the Canadian beef industry, and Tim Darragh of Bayer for a product spotlight! To round out the show, Haney gives... Read More

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates those efforts is essential. In this special episode, Neil Skolnik speaks with Nihar Desai about the challenges of managing chronic kidney disease and diabetes. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Nihar Desai, MD, MPH, Associate Professor of Medicine and Associate Chief of the Section of Cardiovascular Medicine at Yale University School of Medicine, Investigator at the Center for Outcomes Research and Evaluation, and Medical Director for Value Innovation at the Yale New Haven Health System. Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1) :S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

George Schultze discusses a choppy market environment and explains why he favors individual stock selection over broad market exposure. He shares a bullish outlook on energy producers, argues the Mag 7 are overvalued, and highlights Bayer as an undervalued opportunity with significant upside potential.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Sermon delivered on the Feast of the Assumption of the Blessed Virgin Mary, 2026, at Queen of All Saints chapel in Pottstown, Pennsylvania, by Rev. Tobias Bayer. Epistle: Judith 13, 22-25; 15, 10 | Gospel: Luke 1, 41-50

Sermon delivered on the Feast of St. Joachim, Father of the Blessed Virgin Mary, and the Twelfth Sunday After Pentecost, 2026, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer. Epistle: Ecclus. 39, 6-14 | Gospel: Matt. 1, 1-16.

Happy Sunday, liebes Team. Ich schreibe euch das Intro hier heute live aus Ingolstadt, wo gleich der Supercup der Damen stattfindet. Bayern gg Wolfsburg und wir haben unsere nächste Live Folge, in Kooperation mit dem Bayer. Fußball Verband aufgenommen. Wir haben mit der mächtigsten Frau im Funktionärswesen im deutschen Fußball gesprochen. Wir lernen sie kennen, blicken auf ihre DREISSIG Jahre beim DFB zurück. Sie sagt uns, wie sie in schwierigen Situationen zu ihrer eigenen Stärke findet, ihren Take zu Frauenquoten, ob sie die erste DFB-Präsidentin wird und was DIE Tennisspielerin unserer Zeit mit dem Ganzen zu tun hat, gibt es alles heute in unserer neuen Folge. Ein fettes Shoutout an den BfV und unseren Cutter Andy, der eine Nachtschicht für uns eingelegt hat und jetzt macht euch bereit für DFB-Vizepräsidentin: Heike Ullrich. **Schnitt und Postproduktion: Andy Aksen** https://www.aksenmedia.de/ https://www.linkedin.com/in/andyaksen/

John welcomes David Remnick, editor of The New Yorker, to discuss his recent viral podcast interview with DSA co-chair Megan Romer and his latest magnum opus on Israel. Remnick confesses to being "startled" by Romer's glaring “lack of fluency” with DSA's official positions. (He also confesses to having worn a Democratic Socialist Organizing Committee button in college.) And he offers a vivid account of his fifth reporting trip to Israel since October 7, 2023; a portrait of Bibi Netanyahu's main opponent, Gadi Eisenkot, in the forthcoming Israeli election; and an analysis of the campaign's stakes for the Jewish state and the Palestinians.Bayer is empowering American farms with the smart tools and accurate data needed to confidently advance regenerative agriculture, improving soil health for a sustainable future.

Hosts Fran Chismar and Tom Knezick connect with Travis Bayer of Pathos Wildlife to discuss the discovery of the Cozumel Fox. Topics include learning what we know about the Cozumel Fox, how long it was thought to be extinct and how it was rediscovered, what technology is needed to learn more about this animal, how we can help protect and preserve this species, and what obstacles are in the way of accomplishing this mission.  Music by Egocentric Plastic Men, Outro music by Dave Bennett. Follow Pathos Wildlife Here. Have a question or a comment?  Call (215) 346-6189. Follow Native Plants Healthy Planet – Website / Instagram / Facebook / YouTube Follow Fran Chismar Here. Buy a T-shirt, spread the message, and do some good. Visit our store Here! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ever wonder how Around the Farm got started? Tom and Andy share the story behind the podcast, FieldView, and their careers at Bayer.   In this special episode of Around the Farm, hosts Tom Verseman and Andy Folta take listeners behind the scenes of the podcast while sharing the latest updates coming to Climate FieldView. They discuss their career journeys at Bayer Crop Science, lessons they've learned working with growers, memorable podcast moments, and how Around the Farm evolved into one of agriculture's longest-running branded podcasts. Plus, producer Matt Beebe joins the conversation to share the story behind the show's creation and what he's learned from years of telling farmers' stories. Check out "A Farmer's Journey" Here: https://youtube.com/playlist?list=PLkl0uVt1isu_n2Us1iBYrsQ5kutMJBUlE&si=lqnoi8vFmS8W_jiZ

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Philipp Vetter über Entspannung an der Inflationsfront, Übernahme-Euphorie bei Workday und den Aufstieg von Reddit. Außerdem geht es um Workday, Sandisk, Western Digital, Netflix, Hertz, Cisco, Cerebras, Coherent, TKMS, Thyssenkrupp, Vincorion, RWE, Sixt, Secunet, Hellofresh, Energiekontor, Evotec, Birkenstock, Palantir, Nebius, Reddit, AvalonBay, Volkswagen, Adidas, Deutsche Bank, SAP, Siemens, Bayer, Commerzbank, Deutsche Börse, Deutsche Telekom, Siemens Healthineers, iShares Core FTSE 100 (WKN: 552752), BIT Global Technology Leaders (WKN: A2N812) und ARK Innovation ETF (WKN: A408AW). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent auf dein Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Fungicide resistance is a growing concern around the world, but Canadian growers still have an opportunity to stay ahead of it by learning from regions where resistance is already well established. Speaking at Bayer Crop Science's Fungicide Resistance Workshop at Guelph, Ont., Bayer global fungicide lead Dr. Andreas Mehl says Canada's relatively low fungicide use... Read More

Welcome to RealAg Radio with your host Shaun Haney! Today on the show, Haney is joined by Mark Walker of the Canadian Oilseed Processors Association to talk canola crush and biofuels, Justin Gratton of Bayer for a spotlight interview, and Eric Snodgrass of Nutrien for a fall/harvest weather forecast. 01:34 - Biofuel talk with Mark... Read More

John welcomes author Jim Windolf to discuss his new book, “Where the Music Had to Go: How Bob Dylan and The Beatles Changed Each Other—and the World.” Windolf details the revelations and insights unearthed during the five years he spent researching and writing the first full-scale dual biography of two musical acts whose artistic and cultural impact is unparalleled in pop music history—and the surprising degree to which they motivated, inspired, and transformed each other in the process.Bayer is empowering American farms with the smart tools and accurate data needed to confidently advance regenerative agriculture, improving soil health for a sustainable future.

John welcomes back former Wisconsin Democratic Party chairman Ben Wikler to discuss this week's headline-making Senate primary in Michigan, next week's gubernatorial primary in Wikler's home state, and his new book, “This Is The Plan: How to End America's Meltdown and Save Democracy.” Wikler examines Abdul El-Sayed's narrower-than-expected win over Haley Stevens; the startling rise of 37-year-old state representative and Democratic Socialists of America stalwart Francesca Hong to frontrunner status in the Badger State's governor's race; and just how freaked out mainstream Democrats should feel about their party's ongoing wet, hot, DSA summer.Bayer is empowering American farms with the smart tools and accurate data needed to confidently advance regenerative agriculture, improving soil health for a sustainable future.

John welcomes Rolling Stone writer Jonathan Bernstein to discuss the life, music, and legacy of Irish singer-songwriter Glen Hansard, who died tragically last week in a motorcycle crash at 56. Bernstein, who published a moving tribute to Hansard in the wake of his death, traces Glen's rise from Dublin busker to Oscar-winning star of the movie “Once” — and wrestles with why the death of this particular artist unleashed an unexpectedly large and intense outpouring of grief and appreciation across generations and around the world. Bayer is empowering American farms with the smart tools and accurate data needed to confidently advance regenerative agriculture, improving soil health for a sustainable future.

DISCLAIMER: This video is a historical documentary about medicine, pharmacy, and substance use in 19th-century America. It is intended for educational and informational purposes only. Nothing in this video promotes, encourages, or provides instruction for the use of any illegal substance. Many of the substances discussed were legal during the period covered but are now controlled substances. They caused enormous harm, addiction, and loss of life, both then and now. This channel does not condone or promote illegal drug use of any kind. If you or someone you know is struggling with substance abuse, help is available through the SAMHSA National Helpline at 1-800-662-4357, a free, confidential, 24/7 resource.   This is a documentary-style look at pharmaceutical use on the American frontier. We cover the history of morphine and the hypodermic syringe, the myth of the Civil War Soldier's Disease, the real history of opium dens in mining towns like Virginia City, the first anti-opium laws in American history, and the truth behind certain movies like Tombstone and Wild Bill. We also dig into the history of cocaine in patent medicine, whether cowboys really smoked cannabis, Quanah Parker and his advocacy of peyote, Doc Holliday's use of laudanum, and how Bayer marketed heroin as a cough remedy in 1898.   Wild West Quiz - https://wildwestquiz.com/   Check out the website! https://www.wildwestextra.com/   Email me! https://www.wildwestextra.com/contact/   Free Newsletter! https://wildwestjosh.substack.com/   Buy Me A Coffee!  https://buymeacoffee.com/wildwest   Join Patreon for ad-free bonus content! https://www.patreon.com/wildwestextra   Merch! https://wildwestextramerch.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

The gap between what you want and where you are isn't bad luck. It's a belief you made as a kid. David Bayer, author of A Changed Mind, calls it the Golden Equation: desire plus non-resistance equals your result. The block isn't the wanting. It's the meaning you attach to not having it yet. Somewhere between 40 and 60, the exact strategy that made you successful starts to suffocate you. Bayer calls it the Core Program, the compensation you built around a childhood wound that's finally asking to be healed. He spent years numbing himself with drugs, alcohol, sex and pornography before hitting bottom at 33. What got him sober wasn't willpower. It was learning to stop fighting his own thoughts. You don't need more hustle. You need less resistance. This conversation shows you exactly where yours is hiding. David's Website David on Instagram David on YouTube Take The Limiting Belief Assessment! A Changed Mind: Go Beyond Self Awareness, Rewire Your Brain & Reengineer Your Reality Amazon Audiobook In this episode you will: Learn the Golden Equation for turning desire into consistent results without hustle Discover why your Core Program hijacks your success between ages 40 and 60  Overcome limiting beliefs using David Bayer's Decision Matrix from A Changed Mind  Recognize the difference between primal states and powerful states in your nervous system  Build a personal relationship with a higher power through David's communion journaling practice For more information go to https://lewishowes.com/1954 More SOG episodes we think you'll love: Lewis Howes Solo [Ignore your limiting beliefs] Price Pritchett Katie Clarke Get More From Lewis! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.